Halofuginone

Drug Profile

Halofuginone

Alternative Names: Halofuginone hydrobromide; HT-100; Stenorol™; Tempostatin™

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Collgard Biopharmaceuticals
  • Developer Akashi Therapeutics; Collgard Biopharmaceuticals
  • Class Antifibrotics; Piperidines; Quinazolinones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Collagen type I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scleroderma; Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Discontinued Bladder cancer; Cancer; Coronary artery restenosis; Hepatic fibrosis; Kidney disorders; Renal fibrosis; Scleroderma

Most Recent Events

  • 21 Apr 2017 Akashi Therapeutics terminates the HALO-DMD-03 phase II trial for Duchenne muscular dystrophy in USA (NCT02525302)
  • 21 Apr 2017 Akashi Therapeutics terminates the phase II HALO extension trial for Duchenne muscular dystrophy in USA as the dosing was stopped (PO) (NCT01978366)
  • 22 Mar 2017 Akashi Therapeutics plans the HALO-DMD-04 trial for Duchenne muscular dystrophy in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top